메인 콘텐츠로 건너뛰기

MAXCYTE, INC.(MXCT) 주가

MXCT

$1.40▼ 0.03 (−2.10%)10/23 기준 · 지연 시세 · 10/25 21:24 KST 확인
일별 종가(배당 조정) · 15분 지연 · Yahoo Finance고급 차트 ↗

주요 지표

시가총액
$144.5M
PER (예상)
-5.68
PBR
0.94
베타
1.49
52주 최저
$0.64
52주 최고
$1.80
평균 거래량(10일)
2.4M
발행주식수
103.2M

기업 개요

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Healthcare · Medical Devices

SEC 공시

전체 ›

MAXCYTE, INC. 실적 발표일

한국시간 11월 11일(수) 새벽

미국 동부 11월 10일(화) 장 마감 후 · 일정은 회사 사정으로 바뀔 수 있습니다.

실적 캘린더 보기